A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)
Summary
- Eligibility
- for people ages 1 month to 17 years (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Jeffrey Fineman
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Jeffrey Fineman
Professor, Pediatrics, School of Medicine. Authored (or co-authored) 207 research publications
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Actelion
- ID
- NCT02932410
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Last Updated